Redeye provides an update after CLS and ClearPoint reached a long-term agreement on the future ramp-...
Redeye has updated its estimates and valuation following Heliospectra’s Q1 2026 report.
Nelly’s Q1 report fell short of our expectations. Sales fell 2% y/y while EBIT, due to higher admin ...
The key conclusion from Siili’s Q1 miss is that the Finnish market is adopting the AI transition slo...
Q1/26 reflects near-term cost headwinds from recent acquisitions masking improving underlying moment...
Hyresintäkterna minskade marginellt till 15,4 MEUR (-1%) och driftnettot till 14,0 MEUR (-4%), främs...
Redeye is quite surprised by the very strong order bookings in the first quarter, which were 41% hig...
Redeye leaves a comment following OncoZenge’s announcement of conditional acceptance of its Clinical...
* Sales +3% vs. ABGSCe (-14% y-o-y), adj. EBIT +39% vs.
Prisma visar stark tillväxt Q1 2026: fastighetsvärdet steg 37 % till över 10 mdkr.
Redeye comments on Neola Medical’s rights issue. We view the announcement as expected, and as we had...
FM Mattsson (FMM B) has outpaced much of the market with a ~80% return the last year.
Siili's Q1 came in below our estimates with sales declining -14% y/y.
Redeye provides an initial comment on the Q1 2026 report from Sdiptech.
Genovis delivered a Q1 report broadly in line with our estimates, meeting our sales projections show...
Alcadon delivered Q1/26 adj. EBITA of SEK 25m, +15% y/y and 3% above our expectation.
* Return to high organic growth (+41% vs. ABG +29%) * Middle Eastern conflict behind more cautious F...
Nelly Group's Q1 report was soft, with net sales of SEK 243m, down 2% y/y and 5% below SEB.
Aspo Q1 figures were relatively close to estimates.
YIT’s Q1 results corresponded to our expectations, with revenue of EUR 399m (Evli EUR 410m) and adj.
